Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 16, 2021 at 11:32 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Aerie’s dry eye disease drug may not have met the primary endpoints it’s chosen for a Phase IIb study, but that’s not stopping the biotech from powering through Phase III — and steering toward a field with plenty of rivals.

    article source